Unicharm (8113) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Jan–Sep 2026 net sales rose 5.1% to ¥729,342m and core operating income increased 3.3% to ¥89,467m despite higher raw-material costs.
Growth was led by Pet Care and other businesses; parent-attributable profit declined 6.6% to ¥56,733m.
Financial highlights
Net sales were ¥729,342m versus ¥694,225m; core operating income was ¥89,467m versus ¥86,649m, with a 12.3% margin, down 0.2pp.
Profit before tax fell 0.7% to ¥92,826m; profit for the period declined 2.6% to ¥67,135m, and parent-attributable profit fell 6.6% to ¥56,733m.
EBITDA was ¥129.1bn, up 0.2%; basic EPS was ¥32.88 versus ¥34.68 a year earlier.
Total comprehensive income rose to ¥65,524m from ¥49,034m, supported by lower translation losses.
Outlook and guidance
FY2026 guidance unchanged: net sales ¥1,015,000m, core operating income ¥113,000m, profit before tax ¥113,500m, parent-attributable profit ¥70,000m and basic EPS ¥40.68.
Jan–Sep progress was 71.9% for sales, 79.2% for core operating income, 81.8% for profit before tax and 81.0% for attributable profit.
The 4Q core operating income target is ¥23.5bn; value transfer, sales growth, productivity gains and SG&A control are expected to offset higher raw-material and logistics costs.
Latest events from Unicharm
- Record FY2023 results; FY2024 guidance targets further highs as value shifting offsets costs.8113
Q4 2023 - Record sales and profit growth, but profit guidance cut amid cost pressures and global risks.8113
Q2 2026 - Q1 FY2026 saw higher sales and profit, but net profit fell due to lower other income.8113
Q1 2026 - Profits fell in FY2025, but FY2026 forecasts strong recovery and higher dividends.8113
Q4 2025 - Sales and core profit declined, but profit attributable to owners rose 2.0% YoY.8113
Q3 2025 - Sales and profits fell, but resilient regions and cost controls support a recovery outlook.8113
Q2 2025 - Record sales and profit growth, higher dividend, and a positive outlook despite uncertainties.8113
Q2 2024 - Record sales and profit growth, with strong personal and pet care and rising dividends.8113
Q3 2024 - Net profit jumped in Q1 FY2025 despite lower sales, aided by insurance proceeds.8113
Q1 2025